Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.

Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.

That's because there has been a string of negative developments over the past several months, including three deaths from liver failure of patients taking Sarepta's DMD drugs - which led to a pause in ...

Sarepta stock jumped after the drugmaker resumed shipments of the medicine Elevidys, previously paused by request by the FDA, ...

Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to close at $2.42 apiece ...

The lack of a trade agreement between the United States and China could lead to a significant drop in Chinese exports to the ...

"This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such ...

Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its ...

The Food & Drug Administration is investigating the death of an 8‑year‑old following Elevidys gene therapy for Duchenne ...

US stocks end up on earnings, data showing a resilient economy and trade deall optimism. S&P 500 and Nasdaq score records again.

View the latest Sarepta Therapeutics Inc. (SRPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...